Women's Health & STIs Screening & Diagnostic Portfolio

For flexibility and performance based on clinical requirements
are acquired every
day worldwide1
Chlamydia, Gonorrhoea,
Syphilis and Trichomoniasis
New infections each yearNew infections each year
Are curable1
Experience at least one episode
of vaginitis/vaginosis
New infections each year
in their lifetime2

BD is committed to continued innovation
to support you with an improved diagnostics portfolio,
with efficient sample processing and accurate results

The BD MAX™ System, a fully automated, molecular platform providing rapid results for low to mid-volume testing needs

The BD COR™ System, a next generation fully automated platform for high-throughput screening of STIs and infectious disease*

  • Further assays are in development including a next-generation CT/GC/TV Assay with expanded claims, Mgen (Mycoplasma genitalium) and Vaginal Panel. Please contact a BD representative for more information.

*The BD COR™ MX module and all related assays are currently under development, not available for sale yet.

CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae; STI, sexually transmitted infection; TV, Trichomonas vaginalis

1. World Health Organization. Sexually transmitted infections. Available at: Accessed February 11, 2020.
2. Workowski KA and Bolan GA. MMWR Recomm Rep. 2015;64(RR-03):1-137.

Contact us

to discuss how we can support you with screening and diagnosis of STIs